Back to search

Peptide record

TPDB92097

Hymenochirin - 1B H-0 Antibacterial Anticancer Antidiabetic Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
29 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92097
Hymenochirin - 1B H-0
Antibacterial Anticancer Antidiabetic Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cardiometabolic peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 dbACP AFP-GFuse Antifungipept CAFPdb AVPpred-BWR APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 29-aa standard natural multi-activity (Antibacterial, Anticancer, Antidiabetic, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
IKLSPETKDNLKKVLKGAIKGAIAVAKMV-NH2
Physicochemical Analysis
C139H251N37O37S1
RCQHFWY
K
3064.81
10.65
7
2
14
+5
8.03
0.169
124.48
Mammalian: 20 hour Yeast: 30 min E.coli: >10 hour
0
0.00
3
Residue Composition
number
4
A
0
R
1
N
1
D
0
C
1
E
0
Q
2
G
0
H
3
I
3
L
7
K
1
M
0
F
1
P
1
S
1
T
0
W
0
Y
3
V
Amino Acid Distribution
A: 4 R: 0 N: 1 D: 1 C: 0 E: 1 Q: 0 G: 2 H: 0 I: 3 L: 3 K: 7 M: 1 F: 0 P: 1 S: 1 T: 1 W: 0 Y: 0 V: 3
Chemical Descriptors
29
C139H251N37O37S1
3064.81
10.65
+5
8.03
0.169
Amidation
L
Linear
Free
Antimicrobial and Anticancer Host Defense Peptide
Hymenochirus boettgeri
Evidence Records 7 records
Evidence 1 Activity

Activity

IC50
IC50 = 15.22 ± 0.21 µM
Anticancer
15.22

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 12.76 ± 0.43 µM
Anticancer
12.76

Target

Colon Cancer
HCT-116
Colon

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 3 Activity

Activity

IC50
IC50 = 8.07 ± 0.21 µM
Anticancer
8.07

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 4 Activity

Activity

20% cell viability at 10 µM
Anticancer

Target

Lung Cancer
NCI-H-1299
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 5 Activity

Activity

40% cell viability at 10 µM
Anticancer

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 6 Activity

Activity

10% cell viability at 50 µM
Anticancer

Target

Lung Cancer
NCI-H-460
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 7 Activity

Activity

30% cell viability at 20 µM
Anticancer

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019